William Blair Investment Management LLC lowered its stake in Humana Inc. (NYSE:HUM – Free Report) by 9.7% during the third quarter, Holdings Channel reports. The institutional investor owned 30,854 shares of the insurance provider’s stock after selling 3,307 shares during the period. William Blair Investment Management LLC’s holdings in Humana were worth $11,773,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of HUM. BlackRock Inc. bought a new position in Humana in the 2nd quarter valued at about $4,138,160,000. Pzena Investment Management LLC bought a new stake in shares of Humana during the second quarter worth approximately $1,749,014,000. Assenagon Asset Management S.A. boosted its holdings in shares of Humana by 20,126.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock worth $479,053,000 after acquiring an additional 1,249,272 shares during the period. Legal & General Group Plc acquired a new position in shares of Humana in the second quarter valued at approximately $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of Humana in the second quarter valued at approximately $314,922,000. 92.38% of the stock is owned by institutional investors.
Insider Activity
In related news, insider Joseph Ventura sold 5,495 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the transaction, the insider owned 21,910 shares in the company, valued at approximately $9,505,653.50. This trade represents a 20.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.20% of the company’s stock.
Humana Trading Up 0.1%
Shares of NYSE:HUM opened at $450.38 on Monday. The company has a market capitalization of $54.09 billion, a P/E ratio of 43.81, a P/E/G ratio of 2.14 and a beta of 0.65. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $456.50. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.65 and a quick ratio of 1.65. The business’s 50 day simple moving average is $408.53 and its 200 day simple moving average is $316.91.
Humana (NYSE:HUM – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. The firm had revenue of $41.16 billion for the quarter, compared to analyst estimates of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company’s revenue was up 26.1% on a year-over-year basis. During the same quarter last year, the company earned $3.24 EPS. Humana has set its FY 2026 guidance at 9.500- EPS. On average, research analysts anticipate that Humana Inc. will post 9.66 EPS for the current fiscal year.
Humana Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be issued a dividend of $0.8850 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana’s dividend payout ratio is 34.44%.
Analysts Set New Price Targets
A number of brokerages have recently weighed in on HUM. Mizuho increased their target price on Humana from $468.00 to $495.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 13th. UBS Group boosted their price target on Humana from $405.00 to $495.00 and gave the company a “neutral” rating in a research note on Monday, October 12th. Barclays upped their price objective on Humana from $582.00 to $587.00 and gave the company an “overweight” rating in a report on Monday, November 9th. Bank of America upgraded Humana from a “neutral” rating to a “buy” rating and set a $500.00 price objective on the stock in a research report on Wednesday, July 29th. Finally, Oppenheimer lifted their target price on Humana from $475.00 to $525.00 and gave the stock an “outperform” rating in a report on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $476.52.
View Our Latest Analysis on Humana
About Humana
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Read More
- Five stocks we like better than Humana
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
